All stocks today
71229 stocks real-time data.
All stocks today

Stock quotes

Stock market live

Historical stock prices

Stocks market capitalization

Dividend stocks

Stock earnings

Stock revenue

Stock ratings. Where to invest?

TG Therapeutics, Inc. revenue reports

TG Therapeutics, Inc. financial reports, TG Therapeutics, Inc. annual revenue in 2024. When does TG Therapeutics, Inc. report revenue?
Add to widgets
Added to widgets

TG Therapeutics, Inc. total revenue, net income and dynamics of changes in US dollar today

TG Therapeutics, Inc. net income is now -90 628 000 $. The dynamics of TG Therapeutics, Inc. net income went down. The change was -2 410 000 $. These are the main financial indicators of TG Therapeutics, Inc.. TG Therapeutics, Inc. online financial report chart. The financial graph of TG Therapeutics, Inc. shows the values and changes of such indicators: total assets, net income, net revenue. TG Therapeutics, Inc. total revenue on the graph is shown in yellow.

Report date Total revenue
Total revenue refers to the total receipts from sales of a given quantity of goods or services. It is the total income of a business and is calculated by multiplying the quantity of goods sold by the price of the goods.
and Change (%)
Comparing current quartal report this year to quartal report last year.
Net income
Net income is an entity's income minus cost of goods sold, expenses and taxes for an accounting period.
and Change (%)
Comparing current quartal report this year to quartal report last year.
31/03/2021 793 000 $ +1 986.840 % ↑ -90 628 000 $ -
31/12/2020 38 000 $ - -88 218 000 $ -
30/09/2020 38 000 $ - -87 163 000 $ -
30/06/2020 38 000 $ - -52 884 000 $ -
30/09/2019 38 000 $ - -61 930 000 $ -
30/06/2019 38 000 $ - -36 213 000 $ -
31/03/2019 38 000 $ - -35 156 000 $ -
31/12/2018 38 000 $ - -53 860 000 $ -
30/09/2018 38 000 $ - -33 951 000 $ -
30/06/2018 38 000 $ - -44 142 000 $ -
31/03/2018 38 000 $ - -41 529 000 $ -
31/12/2017 38 095 $ - -30 859 767 $ -
30/09/2017 38 096 $ - -31 535 652 $ -
30/06/2017 38 095 $ - -28 353 084 $ -
Show:
to

TG Therapeutics, Inc. financial report charts

The dates of the latest financial statements of TG Therapeutics, Inc.: 30/06/2017, 31/12/2020, 31/03/2021. Dates and dates of financial statements are established by the laws of the country where the company operates. The latest date of the financial report of TG Therapeutics, Inc. is 31/03/2021. Gross profit TG Therapeutics, Inc. is the profit a company makes after deducting the costs of making and selling its products, or the costs of providing its services. Gross profit TG Therapeutics, Inc. is 654 000 $

TG Therapeutics, Inc. quarterly report dates

Cost of revenue TG Therapeutics, Inc. is the total cost of producing and distributing of products and services of a company. Cost of revenue TG Therapeutics, Inc. is 139 000 $ Total revenue TG Therapeutics, Inc. refers to the total receipts from sales of a given quantity of goods or services. It is the total income of a business and is calculated by multiplying the quantity of goods sold by the price of the goods. Total revenue TG Therapeutics, Inc. is 793 000 $ Operating income TG Therapeutics, Inc. is an accounting figure that measures the amount of profit realized from a business's operations, after deducting operating expenses such as wages, depreciation and cost of goods sold (COGS). Operating income TG Therapeutics, Inc. is -89 202 000 $

Net income TG Therapeutics, Inc. is an entity's income minus cost of goods sold, expenses and taxes for an accounting period. Net income TG Therapeutics, Inc. is -90 628 000 $ Current assets TG Therapeutics, Inc. is a balance sheet item that represents the value of all assets that can reasonably expect to be converted into cash within one year. Current assets TG Therapeutics, Inc. is 535 013 000 $ Total assets TG Therapeutics, Inc. refers to the total amount of assets owned by a person or entity. Total assets TG Therapeutics, Inc. is 548 699 000 $

31/03/2021 31/12/2020 30/09/2020 30/06/2020 30/09/2019 30/06/2019 31/03/2019 31/12/2018 30/09/2018 30/06/2018 31/03/2018 31/12/2017 30/09/2017 30/06/2017
Gross profit
Gross profit is the profit a company makes after deducting the costs of making and selling its products, or the costs of providing its services.
654 000 $ 38 000 $ 38 000 $ 38 000 $ 38 000 $ 38 000 $ 38 000 $ 38 000 $ 38 000 $ 38 000 $ - - - -
Cost of revenue
Cost of revenue is the total cost of producing and distributing of products and services of a company.
139 000 $ - - - - - - - - - - - - -
Total revenue
Total revenue refers to the total receipts from sales of a given quantity of goods or services. It is the total income of a business and is calculated by multiplying the quantity of goods sold by the price of the goods.
793 000 $ 38 000 $ 38 000 $ 38 000 $ 38 000 $ 38 000 $ 38 000 $ 38 000 $ 38 000 $ 38 000 $ 38 000 $ 38 095 $ 38 096 $ 38 095 $
Operating revenue
Operating revenue is revenue generated from a company's primary business activities. For example, a retailer produces revenue through merchandise sales, and a physician derives revenue from the medical services he/she provides.
- - - - 38 000 $ 38 000 $ 38 000 $ 38 000 $ 38 000 $ 38 000 $ 38 000 $ 38 095 $ 38 096 $ 38 095 $
Operating income
Operating income is an accounting figure that measures the amount of profit realized from a business's operations, after deducting operating expenses such as wages, depreciation and cost of goods sold (COGS).
-89 202 000 $ -86 782 000 $ -85 722 000 $ -50 845 000 $ -60 861 000 $ -35 544 000 $ -34 689 000 $ -54 150 000 $ -34 328 000 $ -44 345 000 $ -41 577 000 $ -31 034 731 $ -31 585 227 $ -28 425 371 $
Net income
Net income is an entity's income minus cost of goods sold, expenses and taxes for an accounting period.
-90 628 000 $ -88 218 000 $ -87 163 000 $ -52 884 000 $ -61 930 000 $ -36 213 000 $ -35 156 000 $ -53 860 000 $ -33 951 000 $ -44 142 000 $ -41 529 000 $ -30 859 767 $ -31 535 652 $ -28 353 084 $
R&D spending
Research and Development spending - cost of investigative activities to improve existing products and procedures or to lead to the development of new products and procedures.
63 094 000 $ 42 961 000 $ 50 464 000 $ 36 449 000 $ 57 985 000 $ 32 866 000 $ 32 385 000 $ 52 276 000 $ 33 398 000 $ 38 700 000 $ 35 018 000 $ 25 996 108 $ 27 149 050 $ 26 705 799 $
Operating expense
An operating expense is an expenditure that a business incurs as a result of performing its normal business operations.
89 995 000 $ 86 820 000 $ 85 760 000 $ 50 883 000 $ 60 899 000 $ 35 582 000 $ 34 727 000 $ 54 188 000 $ 34 366 000 $ 44 383 000 $ 41 615 000 $ 31 072 826 $ 31 623 323 $ 28 463 466 $
Current assets
Current assets is a balance sheet item that represents the value of all assets that can reasonably expect to be converted into cash within one year.
535 013 000 $ 611 740 000 $ 260 335 000 $ 280 938 000 $ 80 355 000 $ 94 441 000 $ 105 058 000 $ 79 031 000 $ 109 737 000 $ 136 038 000 $ 116 958 000 $ 93 317 400 $ 97 661 296 $ 97 044 477 $
Total assets
Total assets refers to the total amount of assets owned by a person or entity.
548 699 000 $ 625 642 000 $ 273 856 000 $ 294 621 000 $ 93 327 000 $ 106 585 000 $ 117 538 000 $ 83 616 000 $ 114 374 000 $ 140 715 000 $ 120 994 000 $ 97 381 536 $ 101 781 514 $ 101 197 751 $
Current cash
Current cash - the sum of all of the cash a company has on the date of report.
471 514 000 $ 553 439 000 $ 254 154 000 $ 260 512 000 $ 44 675 000 $ 57 228 000 $ 64 349 000 $ 41 958 000 $ 70 718 000 $ 105 672 000 $ 83 484 000 $ 56 717 847 $ 91 842 167 $ 77 602 363 $
Current debt
Current debt is the portion of debt due within a year (12 months) and is listed as a current liability and part of net working capital.
- - - - 80 197 000 $ 55 967 000 $ 60 940 000 $ 38 854 000 $ 40 242 000 $ 36 938 000 $ 224 000 $ 127 614 $ 182 156 $ 152 568 $
Total cash
Total cash - the sum of all of the cash a company has on its books, including petty cash and funds on deposit in a bank.
- - - - - - - - - - 109 077 000 $ 84 716 657 $ 91 842 167 $ 86 411 293 $
Total debt
Total debt is a combination of both short-term and long-term debt. Short-term debts are those that must be paid back within a year. Long-term debt generally includes every liability that must be paid off in more than a year.
- - - - 119 118 000 $ 93 380 000 $ 98 284 000 $ 59 580 000 $ 42 630 000 $ 39 339 000 $ - - - -
Debt ratio
Total debt to total assets - is a financial ratio that indicates the percentage of a company's assets that are provided via debt.
- - - - 127.64 % 87.61 % 83.62 % 71.25 % 37.27 % 27.96 % - - - -
Shareholders equity
Shareholder's equity (SE) is the owner's claim after subtracting total liabilities from total assets.
445 285 000 $ 519 350 000 $ 170 658 000 $ 194 227 000 $ -25 791 000 $ 13 205 000 $ 19 254 000 $ 24 036 000 $ 71 744 000 $ 101 376 000 $ 85 232 000 $ 66 993 055 $ 79 545 766 $ 77 975 018 $
Cash flow
Cash flow is the net amount of cash and cash-equivalents being transferred into and out of a business.
- - - - -33 202 000 $ -35 860 000 $ -33 351 000 $ -33 690 000 $ -33 009 000 $ -34 183 000 $ -28 043 000 $ -21 855 129 $ -22 776 473 $ -26 830 960 $

Last revenue report of TG Therapeutics, Inc. was 31/03/2021. According to last financial report total revenue in TG Therapeutics, Inc. was 793 000 US dollar and changed by +1 986.840% since last year. Net income in TG Therapeutics, Inc. was -90 628 000 $ in last quartal, net income changes to 0%.

Current cash TG Therapeutics, Inc. - the sum of all of the cash a company has on the date of report. Current cash TG Therapeutics, Inc. is 471 514 000 $

TG Therapeutics, Inc. stocks data

TG Therapeutics, Inc. financials